Cargando…

Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines

The research on the anticancer potential of platinum(IV) complexes represents one strategy to circumvent the deficits of approved platinum(II) drugs. Regarding the role of inflammation during carcinogenesis, the effects of non-steroidal anti-inflammatory drug (NSAID) ligands on the cytotoxicity of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barth, Marie-Christin, Häfner, Norman, Runnebaum, Ingo B., Weigand, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056020/ https://www.ncbi.nlm.nih.gov/pubmed/36982792 http://dx.doi.org/10.3390/ijms24065718

Ejemplares similares

Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms
por: Hildebrandt, Jana, et al.
Publicado: (2022)

Novel Nickel(II), Palladium(II), and Platinum(II) Complexes with O,S Bidendate Cinnamic Acid Ester Derivatives: An In Vitro Cytotoxic Comparison to Ruthenium(II) and Osmium(II) Analogues
por: Hildebrandt, Jana, et al.
Publicado: (2022)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
por: Ma, Xiao, et al.
Publicado: (2023)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer
por: Zhang, Guyu, et al.
Publicado: (2019)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants
por: Heinze, Karolin, et al.
Publicado: (2018)

RUNX3 Transcript Variants Have Distinct Roles in Ovarian Carcinoma and Differently Influence Platinum Sensitivity and Angiogenesis
por: Heinze, Karolin, et al.
Publicado: (2021)

Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs
por: Wong, Daniel Yuan Qiang, et al.
Publicado: (2015)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
por: Aputen, Angelico D., et al.
Publicado: (2023)

CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients
por: Heinze, Karolin, et al.
Publicado: (2021)

Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells
por: Zhu, Zhenzhu, et al.
Publicado: (2016)

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells
por: Khoury, Aleen, et al.
Publicado: (2022)

Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions
por: Savino, Salvatore, et al.
Publicado: (2018)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Inhibition of Type IV Secretion Activity and Growth of Helicobacter pylori by Cisplatin and Other Platinum Complexes
por: Lettl, Clara, et al.
Publicado: (2020)

In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
por: Klameth, Lukas, et al.
Publicado: (2017)

Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study
por: Ratzon, Einav, et al.
Publicado: (2016)

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
por: Zhang, Rongrong, et al.
Publicado: (2017)

Disulfide-containing polymer delivery of C527 and a Platinum(IV) prodrug selectively inhibited protein ubiquitination and tumor growth on cisplatin resistant and patient-derived liver cancer models
por: Shang, Kun, et al.
Publicado: (2023)

Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand
por: Liu, Fengfan, et al.
Publicado: (2019)

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
por: Xiang, Dongquan, et al.
Publicado: (2023)

In situ oxidative polymerization of platinum(iv) prodrugs in pore-confined spaces of CaCO(3) nanoparticles for cancer chemoimmunotherapy
por: Wei, Fangmian, et al.
Publicado: (2023)

An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy
por: Liu, Gongyuan, et al.
Publicado: (2023)

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance
por: Papadia, Paride, et al.
Publicado: (2020)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: A Dual-Acting Weapon for Targeting DNA in Cancer Cells
por: Montagner, Diego, et al.
Publicado: (2018)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Cetuximab-decorated and NIR-activated Nanoparticles Based on Platinum(IV)-prodrug: Preparation, Characterization and In-vitro Anticancer Activity in Epidermoid Carcinoma Cells
por: Wang, Yu, et al.
Publicado: (2021)

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
por: Loh, S. Y., et al.
Publicado: (1992)

Platinum resistance in breast and ovarian cancer cell lines
por: Eckstein, Niels
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5bc2d94st0qtcj6et4k3t3457d